Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biomind Labs Inc N.BMND

Alternate Symbol(s):  BMNDF

Healthcare
Biomind Labs Inc. is a Canada-based biotech research and development company. The Company is primarily engaged in biotech platform that integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production with special focus on scientific research, clinical trials and in jurisdictions that open a fast track in the molecule to market lifecycle. Through its acceleration platform, it is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (DMT), 5-MeO-DMT, and mescaline for treating a range of therapeutic indications. 5-MeO-DMT is a powerful psychedelic tryptamine. Under the 5-MeO-DMT Program, the Company is focused on two drug candidates: BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and BMND08: 5-MeO-DMT novel formulation indicated for Alzheimer’s disease. Mescaline is a psychedelic alkaloid of the phenethylamine class. DMT Program is a serotonergic psychedelic.


NEO:BMND - Post by User

Biomind Labs Inc
<< Previous
 Bullboard Posts
User Avatar Image
(86)
•••
Post by whytestockson Feb 29, 2024 10:30am
87 Views
Post# 35906364

Biomind Labs Announces Unprecedented Positive Results of Pha

Biomind Labs Announces Unprecedented Positive Results of Pha
BREAKING NEWS: $BMNDF Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer's DiseaseBiomind Labs Inc. (&#x201C; Biomind &#x201D; or the &#x201C; Company &#x201D;) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeti...BMNDF - Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer's Disease

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities